Eb-Car5-Nk
B2 Thymoma
Beijing BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the B2 Thymoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Regorafenib Istituto Clinico Humanitas | Phase 2 | B |
Cyclophosphamide Beijing Biotech | Phase 1/2 | CC |
Eb-Car30-Nk Beijing Biotech | Phase 1/2 | CC |
Fludarabine Beijing Biotech | Phase 1/2 | CC |
Eb-Carmsln-Nk Beijing Biotech | Phase 1/2 | CC |
Rimiducid Beijing Biotech | Phase 1/2 | CC |
Same molecule, other indications
Eb-Car5-Nk is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →